Positive Clinical Data and Pipeline Expansion
Wave Life Sciences announced positive data for its AATD, DMD, and HD clinical programs, derisked a new modality with RNA editing, and expanded its pipeline with high-impact programs.
Advancement of WVE-007 for Obesity
WVE-007, a GalNAc siRNA for obesity, advanced to the clinic and completed enrollment in the first cohort of the in-light clinical trial.
Strong Financial Position
The company ended the year with $302.1 million in cash and cash equivalents, an increase from $200.4 million the previous year, enabling funding operations into 2027.
Demonstrated RNA Editing in Humans
The Restoration clinical program showed the first-ever clinical demonstration of RNA editing in humans with WVE-006, showing an increase in AAT from baseline.
Progress in Huntington's Disease Treatment
WVE-003 showed potent and durable mutant huntingtin reductions and a statistically significant correlation with slowing of caudate atrophy in Huntington's disease.